M&As this week: 10x Genomics, Atlantic Research Group, AGC

14th December 2018 (Last Updated December 14th, 2018 00:00)

10x Genomics has acquired Spatial Transcriptomics to enter the field of spatial genomics.

10x Genomics has acquired Spatial Transcriptomics to enter the field of spatial genomics.

The acquisition will enable 10x Genomics to gain an insight into the new field and generate a deeper biological understanding.

It will open avenues for the development of novel therapeutics in various areas including oncology and immunology.

The acquisition will also enable the company to increase its presence in Sweden.

10x Genomics and Spatial Transcriptomics are biotechnology companies based in the US and Sweden respectively.

Atlantic Research Group (ARG) has strengthened its clinical trial management portfolio with the acquisition of CCA Clinical Research.

The deal means ARG will grow its workforce to 100 employees to serve their expansive global client base.

ARG is a contract research organisation (CRO) based in the US, while CCA Clinical Research is a British CRO firm.

"Atlantic Research Group (ARG) has strengthened its clinical trial management portfolio with the acquisition of CCA Clinical Research."

AGC has agreed to acquire Boehringer Ingelheim’s subsidiary Malgrat Pharma Chemicals.

The acquisition will provide AGC with access to the Malgrat Pharma’s first FDA-registered pharmaceutical active ingredient-manufacturing plant located in Spain.

The plant is involved in the contract development and manufacturing of synthetic pharmaceuticals.

The transaction will also enable AGC to expand its asset base and increase its presence in the European market.

AGC is a glass manufacturing company based in Japan, while Malgrat Pharma Chemicals is a Spanish synthetic pharmaceuticals manufacturer.

KDA Group has entered a letter of intent (LoI) with Strides Pharma Global to divest its majority stake in its Canadian pharmaceutical division, Pharmapar.

Strides Pharma will acquire 80% of Pharmapar’s issued and outstanding common shares for C$4m ($3m).

The transaction is expected to be closed by December 2018 subject to required approvals, including the final approval from the TSX Venture Exchange.

KDA Group is a Canadian generic drug distributor, while Strides Pharma is a pharmaceutical company based in India.